Molecular Functions of CDK1 in Gastric Tumorigenesis
Molecular Functions of CDK1 in Gastric Tumorigenesis
批准号:
10326393
负责人:
WAEL EL-RIFAI
金额:
$45.4万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-01-12 至 2025-12-31
关键词:
AffectBindingBiologicalBiologyCDC2 geneCancer BiologyCancer EtiologyCancer ModelCancer PatientCarcinogensCell CycleCell DeathCell SurvivalCellsCessation of lifeCisplatinDevelopmentDiagnosisDiagnosticEpigenetic ProcessFutureGeneticGenetic TranscriptionGrowthHelicobacter InfectionsHelicobacter pyloriHumanInfectionInterventionLinkMediatingMolecularMusNF-kappa BOncogenicOncologyOrganoidsOutcomePathologyPersonsPharmacologyPhosphorylationPlayPopulationPositioning AttributePreventivePropertyRefractoryReportingResistanceRisk FactorsRoleSignal PathwaySignal TransductionStimulusStomachStomach CarcinomaSurvival RateTechnologyTherapeuticTimeTissue SampleTranscriptional RegulationUnited StatesWorkbasecancer cellcancer statisticschemotherapeutic agentchemotherapyclinically significantdesignempoweredexperiencegastric carcinogenesisgastric tumorigenesisgenotoxicityhuman tissueimprovedin vitro Modelmalignant stomach neoplasmmouse modelneoplastic cellnovelnovel therapeutic interventionoverexpressionprognosticrefractory cancerresponseself-renewaltherapy resistanttranscription factortranscriptional reprogrammingtranslational study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT/SUMMARY: Gastric cancer is the third leading cause of cancer-related death worldwide. The 2018
global cancer statistics report indicates an estimated over 1,000,000 new cases and an estimated 783,000
deaths in 2018. Gastric cancers are poorly responsive to therapy and have an unfavorable outcome with an
estimated overall 5-year survival rate of approximately 20%. In response to genotoxic stimuli, cancer cells
undergo rewiring and reprogramming of transcription and signaling networks to drive adaption and survival
properties. This reprogramming leads to the development of acquired adaptive properties that promote survival
and expansion of neoplastic cells. Comprehensive analysis approaches have enabled us to identify a biologically
relevant novel signaling axis in gastric cancer. We detected aberrant cytosolic overexpression of CDK1 in human
and mouse gastric cancers. While CDK1 is a well-established cell cycle regulator, we have discovered previously
unreported functions in neoplastic cells in gastric cancer, the focus of this proposal. We found that in response
to genotoxic stimuli, such as infection and chemotherapeutics, the surviving pool of neoplastic cells develop an
acquired adaptive pro-survival response that includes induction of CDK1 and SOX9 transcription factor. We
demonstrate, for the first time, that CDK1 is induced in response to activation of NF-kB transcription activity. At
the same time, CDK1 induces SOX9 through epigenetic mechanisms that include activation of DNMT1 and
suppression of miR-145. Inhibition of CDK1 by genetic or pharmacologic approaches decreased SOX9 level and
activity and induced cancer cell death. Based on novel preliminary results, we hypothesize that activation of
CDK1-SOX9 axis promotes cell survival and expansion of neoplastic cells in response to H. pylori infection and
chemotherapeutic interventions. We have developed three specific aims that include mechanistic, functional,
and translational studies using in vitro models, organoid cultures, mouse models, and de-identified human tissue
samples. In aim 1, we plan to investigate the role of H. pylori infection and NF-kB transcription factor in regulating
CDK1-SOX9 axis. We will also investigate a novel epigenetic link that includes CDK1 and DNMT1 in regulating
SOX9 transcription factor levels and activity. Our second aim will focus on investigating molecular functions and
oncogenic transcription network of CDK1-SOX9 axis. The translational significance will be studied in aim 3 by
investigating therapeutic potential and clinical significance of CDK1-SOX9 functional axis in gastric cancer. We
have assembled a highly collaborative team with experience in advanced molecular technologies, cancer
models, and oncology making us in a unique position to perform the proposed studies. Upon completion of this
work, we expect to unveil a novel druggable paradigm of cross-talk between CDK1 and SOX9 signaling pathways
in gastric tumorigenesis. These molecular interactions not only provide a novel understanding of the biology of
gastric cancer but also offer future translational opportunities for the design of new therapeutic interventions for
gastric cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE A (Administrative Core)
-
批准号:10662324
-
项目类别:
-
资助金额:$10.1万
-
财政年份:2022
-
负责人:WAEL EL-RIFAI
-
依托单位:
Intercepting novel functions of AURKA in gastric tumorigenesis
-
批准号:10663953
-
项目类别:
-
资助金额:$43.54万
-
财政年份:2022
-
负责人:WAEL EL-RIFAI
-
依托单位:
CORE A (Administrative Core)
-
批准号:10407748
-
项目类别:
-
资助金额:$10.98万
-
财政年份:2022
-
负责人:WAEL EL-RIFAI
-
依托单位:
Disruption of Transcription Networks in Esophageal Adenocarcinoma Tumorigenesis
-
批准号:10407744
-
项目类别:
-
资助金额:$157.42万
-
财政年份:2022
-
负责人:WAEL EL-RIFAI
-
依托单位:
Disruption of Transcription Networks in Esophageal Adenocarcinoma Tumorigenesis
-
批准号:10662298
-
项目类别:
-
资助金额:$151.64万
-
财政年份:2022
-
负责人:WAEL EL-RIFAI
-
依托单位:
Elucidating Novel APE1 Redox-Dependent Functions in Esophageal Adenocarcinoma
-
批准号:10662300
-
项目类别:
-
资助金额:$40.57万
-
财政年份:2022
-
负责人:WAEL EL-RIFAI
-
依托单位:
Elucidating Novel APE1 Redox-Dependent Functions in Esophageal Adenocarcinoma
-
批准号:10407745
-
项目类别:
-
资助金额:$41.4万
-
财政年份:2022
-
负责人:WAEL EL-RIFAI
-
依托单位:
Intercepting novel functions of AURKA in gastric tumorigenesis
-
批准号:10515693
-
项目类别:
-
资助金额:$44.43万
-
财政年份:2022
-
负责人:WAEL EL-RIFAI
-
依托单位:
Molecular Functions of CDK1 in Gastric Tumorigenesis
-
批准号:10546490
-
项目类别:
-
资助金额:$45.4万
-
财政年份:2021
-
负责人:WAEL EL-RIFAI
-
依托单位:
Molecular Functions of CDK1 in Gastric Tumorigenesis
-
批准号:10117581
-
项目类别:
-
资助金额:$46.32万
-
财政年份:2021
-
负责人:WAEL EL-RIFAI
-
依托单位:
Tumor Biology Research Program
-
批准号:10190864
-
项目类别:
-
资助金额:$3.89万
-
财政年份:2019
-
负责人:WAEL EL-RIFAI
-
依托单位:
Tumor Biology Research Program
-
批准号:9789588
-
项目类别:
-
资助金额:$3.66万
-
财政年份:2019
-
负责人:WAEL EL-RIFAI
-
依托单位:
Tumor Biology Research Program
-
批准号:10443642
-
项目类别:
-
资助金额:$4.0万
-
财政年份:2019
-
负责人:WAEL EL-RIFAI
-
依托单位:
Tumor Biology Research Program
-
批准号:10670850
-
项目类别:
-
资助金额:$4.12万
-
财政年份:2019
-
负责人:WAEL EL-RIFAI
-
依托单位:
The role of NRF2 in reflux-induced esophageal adenocarcinomas
-
批准号:10331804
-
项目类别:
-
资助金额:$34.41万
-
财政年份:2018
-
负责人:WAEL EL-RIFAI
-
依托单位:
The role of NRF2 in reflux-induced esophageal adenocarcinomas
-
批准号:10083196
-
项目类别:
-
资助金额:$35.11万
-
财政年份:2018
-
负责人:WAEL EL-RIFAI
-
依托单位:
BLR&D Research Career Scientist Award
-
批准号:9343273
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:WAEL EL-RIFAI
-
依托单位:
The Role of Aurora Kinase in Upper Gastrointestinal Adenocarcinomas
-
批准号:9597768
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2017
-
负责人:WAEL EL-RIFAI
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:10480519
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:WAEL EL-RIFAI
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:10594001
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:WAEL EL-RIFAI
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: